Successful treatment of relapsing polychondritis with infliximab.

Abstract

Relapsing polychondritis (RP) is a rare and potentially fatal autoimmune disease in which an inappropriate immune response destroys the cartilage of the ears, larynx and nose. Many therapeutic approaches have been reported. We describe the results obtained with infliximab in a patient with RP unresponsive to conventional therapy. This therapy could be a new weapon to treat refractory RP.

• Authors: C Richez, C Dumoulin, X Coutouly, T Schaeverbeke
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) 2004 Sep-Oct Vol. 22 Issue 5 Pg. 629-31 ISSN: 0392-856X [Print] Italy
• PMID: 15485019 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Adult
• Antibodies, Monoclonal (immunology, therapeutic use)
• Antirheumatic Agents (immunology, therapeutic use)
• Humans
• Infliximab
• Male
• Polychondritis, Relapsing (drug therapy, immunology)
• Treatment Outcome
• Tumor Necrosis Factor-alpha (immunology)